Future Biomarkers for Detection of Ischemia and Risk Stratification in Acute Coronary Syndrome
- 1 May 2005
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 51 (5), 810-824
- https://doi.org/10.1373/clinchem.2004.046292
Abstract
Background: Evaluation of patients who present to the hospital with a complaint of chest pain or other signs or symptoms suggestive of acute coronary syndrome (ACS) is time-consuming, expensive, and problematic. Recent investigations have indicated that increases in biomarkers upstream from biomarkers of necrosis (cardiac troponins I and T), such as inflammatory cytokines, cellular adhesion molecules, acute-phase reactants, plaque destabilization and rupture biomarkers, biomarkers of ischemia, and biomarkers of myocardial stretch may provide earlier assessment of overall patient risk and aid in identifying patients with higher risk of an adverse event. Approach and Content: The purpose of this review is to provide an overview of the pathophysiology and clinical and analytical characteristics of several biomarkers that may have potential clinical utility to identify ACS patients. These biomarkers (myeloperoxidase, metalloproteinase-9, soluble CD40 ligand, pregnancy-associated plasma protein A, choline, ischemia-modified albumin, unbound free fatty acids, glycogen phosphorylase isoenzyme BB, and placental growth factor) have demonstrated promise and need to be more thoroughly evaluated for commercial development for implementation into routine clinical and laboratory practice. Summary: Specifications that have been addressed for cardiac troponins and natriuretic peptides will need to be addressed with the same scrutiny for the biomarkers discussed in this review. They include validating analytical imprecision and detection limits, calibrator characterization, assay specificity and standardization, preanalytical issues, and appropriate reference interval studies. Crossing boundaries from research to clinical application will require replication in multiple settings and experimental evidence supporting a pathophysiologic role and, ideally, interventional trials demonstrating that monitoring single or multiple biomarkers improves outcomes.Keywords
This publication has 75 references indexed in Scilit:
- Acute Coronary Syndrome BiomarkersCirculation, 2004
- From Vulnerable Plaque to Vulnerable PatientCirculation, 2003
- Management of acute myocardial infarction in patients presenting with ST-segment elevationEuropean Heart Journal, 2003
- Neutrophil Infiltration of Culprit Lesions in Acute Coronary SyndromesCirculation, 2002
- Management of acute coronary syndromes in patients presenting without persistent ST-segment elevationEuropean Heart Journal, 2002
- Widespread Coronary Inflammation in Unstable AnginaThe New England Journal of Medicine, 2002
- Association Between Myeloperoxidase Levels and Risk of Coronary Artery DiseaseJAMA, 2001
- Macrophage Myeloperoxidase Regulation by Granulocyte Macrophage Colony-Stimulating Factor in Human Atherosclerosis and Implications in Acute Coronary SyndromesThe American Journal of Pathology, 2001
- Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction: The Joint European Society of Cardiology/ American College of Cardiology CommitteeJournal of the American College of Cardiology, 2000
- Reduction of canine infarct size by bolus intravenous administration of liposomal prostaglandin E1: Comparison with control, placebo liposomes, and continuous intravenous infusion of prostaglandin E1American Heart Journal, 1996